BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12655443)

  • 41. [Administration and dosage of fluorouracil (5-FU) continuous i.v. infusion in patients with non-curative resected/non-resected gastric cancer].
    Yamaguchi A; Isogai M; Hori A; Kawai M; Yamaguchi R; Kubota T; Yamada T; Maeda A
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):567-72. PubMed ID: 8678514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
    Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
    Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
    Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP].
    Ishio T; Kohnoe S; Endo K; Yamamoto M; Ikeda Y; Toh Y; Baba H; Okamura T; Kawamoto K
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1627-30. PubMed ID: 12355950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer].
    Takano S; Oda K; Koda K; Seike K; Takiguchi N; Miyazaki M
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):555-8. PubMed ID: 17431341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapeutic efficacy of intra-peritoneal infusion of cisplatin and continuous intravenous infusion of 5-fluorouracil in gastric cancer patients with peritoneal metastasis].
    Terashima M; Takagane A; Oyama K; Abe K; Araya M; Yonezawa H; Irinoda T; Nakaya T; Shimooki O; Inaba T; Fujiwara H; Saito K
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1806-8. PubMed ID: 10560399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Preliminary clinical evaluation of low-dose CDDP and continuous 5-FU therapy for advanced gallbladder cancer].
    Tsuji A; Morita S; Horimi T; Takasaki M; Takamatsu M; Takahashi I; Shirasaka T
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):233-7. PubMed ID: 10700893
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
    J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
    Baba E; Fujishima H; Kusaba H; Esaki T; Ariyama H; Kato K; Tanaka R; Mitsugi K; Shibata Y; Harada M; Nakano S
    Anticancer Res; 2009 May; 29(5):1727-32. PubMed ID: 19443394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
    Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
    Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical reevaluation of continuous intravenous infusion of 5-fluorouracil--plasma concentrations and clinical dose by continuous intravenous and 60-min infusions].
    Nakatsu T; Yokoyama I; Tsuyuki K; Soh Y; Hanai G; Matsumoto H; Kubo H; Matsumoto K; Nohga K; Koyanagi H
    Gan To Kagaku Ryoho; 1990 Feb; 17(2):253-8. PubMed ID: 2301952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
    Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.